Drug Hypersensitivity Reactions

- Nima Parvaneh, MD
- Children's Medical Center
- TUMS

Adverse drug reactions

Reactions	Example
Predictable	
Overdosage	Acetaminophen – hepatic necrosis
Side-effect	Albuterol – tremor
Secondary effect	Clindamycin – <i>Clostridium difficile</i> pseudomembranous colitis
Drug-drug interaction	Terfenadine/erythromycin – torsade de pointes arrhythmia
Unpredictable	
Intolerance	Aspirin – tinnitus (at usual dose)
Idiosyncratic	Chloroquine – hemolytic anemia in G6PD-deficient patient
Allergic	Penicillin – anaphylaxis
Pseudoallergic	Radiocontrast material – anaphylactoid reaction

- In otherwise normal patients
- Dose-dependent
- Related to the known pharmacologic actions of the drug
- Predictable

- In genetic susceptible individuals
- Dose-independent
- Not related Related to the pharmacologic actions of the drug
- Not predictable

Adverse drug reactions




TABLE 77.1	Gell and Coombs Classification	of Hypersensi	tivity Disorders		
ТҮРЕ	INTERVAL BETWEEN EXPOSURE AND REACTION	EFFECTOR MOLECULE	TARGET OR ANTIGEN	EXAMPLES OF MEDIATORS	EXAMPLES
l Immediate Late phase	<30 min 2-12 hr	lgE	Pollens, food, venom, drugs	Histamine, tryptase, leukotrienes, prostaglandins, platelet- activating factor	Anaphylaxis, urticaria, allergic rhinitis, allergic asthma
ll Cytotoxic antibody	Variable (minutes to hours)	lgM, lgG, lgA	Red blood cells, platelets	Complement	Hemolytic anemia, thrombocytopenia, Goodpasture syndrome
III Immune complex	1-3 wk after drug exposure	Antigen- antibody complexes	Blood vessels, liver, spleen, kidney, lung	Complement, anaphylatoxin	Serum sickness, hypersensitivity pneumonitis
IV Delayed type	2-7 days after drug exposure	Lymphocytes	Mycobacterium tuberculosis, chemicals	Cytokines (IFN-γ, TNFα, GM-CSF)	TB skin test reactions, contact dermatitis, graft-versus-host disease

CSF, Cerebrospinal fluid; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-γ; TB, tuberculosis; TNFα, tumor necrosis factor-α.

Urticaria

Morbilliform rash



Erythema multiforme

•Evaluation of the clinical history:

- •The timing of the reaction
- •The nature of the drugs involved
- •The dosage and rout of administration
- •The Hx of a previous exposure
- Medical/genetic background
- •The severity of reaction
- Differential Dxs

Drug allergy labeling

 Approximately 90% of patients with a clinical history of penicillin allergy do not have evidence of penicillin-specific IgE antibodies



Risk Factors for Hypersensitivity Reactions to Drugs


- Prior exposure
- Previous reactions
- Age (20-49 yr)
- Route of administration (parenteral or topical)
- Dose (high)
- Dosing schedule (intermittent)
- Genetic predisposition (slow acetylators, HLA associations)
- BUT NOT ATOPY

Immediate allergic reactions to Penicillin:

A model to show clinical complexity of drug allergy

Drug allergy labeling

A penicillin-allergy label is usually acquired in childhood



Fewer efficacious antibiotic choices

More toxic effects associated with alternative antibiotics

Use of broad-spectrum antibiotics

More postoperative surgical-site infections


Antibiotic resistance

Higher rates of *C. difficile* infection Use of more costly antibiotics

Increased length of hospital stays

<5% Labeled as allergic to penicillin are truly allergic


Mechanism of immediate DHRs



Sensitization phase

Re-exposure

Anaphylaxis is highly likely when any one of the following three criteria is fulfilled:





Signs and symptoms of anaphylaxis

TABLE 75.4Signs and Symptoms ofAnaphylaxis:Frequency of Occurrence

Signs/Symptoms	Approximate Percentage of Cases
Cutaneous Urticaria Angioedema Flushing Pruritis Other rash	80-90
Respiratory Rhinorrhea, congestion Stridor Dysphonia Shortness of breath Chest tightness Wheezing Cyanosis	70
Cardiovascular Chest pain Tachycardia Bradycardia Hypotension Dysrhythmias Cardiac arrest	45
Gastrointestinal Abdominal pain Nausea, vomiting Diarrhea	45
Central Nervous System Sense of impending doom Altered mental status Dizziness Confusion Headache	15

Modified from Zilberstein et al.²





Severity grading system of immediate type 1 hypersensitivity reactions

	Grade Severit		Description
	1	Mild	Symptoms are limited to the skin (<i>e.g.,</i> flushing) or involve a single organ/system and are mild (<i>e.g.,</i> mild back pain).
oinephrine vated Tryptase	2	Moderate	Symptoms involve at least two organs/ systems (<i>e.g.,</i> flushing and dyspnea), but there is no significant decrease in blood pressure or oxygen saturation.
	3	Severe	Symptoms typically involve at least two organs/systems, and there is a significant decrease in blood pressure (systolic ≤90 mm Hg and/or syncope) and/or oxygen saturation (≤92%).

Ер

Eleva

Diagnostic measures:

- Search for drug specific specific IgE :
 - Skin tests
 - In vitro tests
- Drug Provocation tests




Diagnosis of Anaphylaxis: elevated tryptase level

Penicillin allergenic determinants


- Minor determinants •
 - MDM •
 - Penicillin G ٠





ÓН

Penicilloate



Protein

Н

0 = C

NH

CH₃

CH₃

COOH

Penilloate

Major determinant • • Pre-Pen



Positive Penicillin Skin-Test Patterns Among Patients Reporting a History of Penicillin Allergy: Results in Three Studies Using PPL, Benzylpenicillin, Benzylpenicilloate, Benzylpenilloate, and Amoxicillin Reagents

Reagent	Macy et al, 1997 ⁴³ N = 60 ^a n (%)	Lin et al, 2010 ⁴⁵ N = 243 ^b n (%)	Geng et al, 2017 ⁴⁷ N = 107 ^b n (%)
Positive to specified reagent, alone or in combination			
Penicilloyl-polylysine (PPL) ^c	41 (68.3%)	157 (64.6%)	39 (36.4%)
Benzylpenicillin	9 (15.0%)	111 (45.7%)	24 (22.4%)
Benzylpenicilloate	5 (8.3%)	90 (37.0%)	58 (54.2%)
Benzylpenilloate	8 (13.3%)	84 (34.6%)	23 (21.5%)
Amoxicillin	4 (6.7%)	75 (30.9%)	41 (38.3%)
Positive to specified reagent only			
PPL only	24 (40.0%)	45 (18.5%)	13 (12.1%)
Benzylpenicillin only	2 (3.3%)	16 (6.6%)	2 (1.9%)
Benzylpenicilloate only	4 (6.7%)	7 (2.9%)	25 (23.4%)
Benzylpenilloate only	7 (11.7%)	16 (6.6%)	3 (2.8%)
Amoxicillin only	1 (1.7%)	14 (5.8%)	8 (7.5%)
Positive to one or more specified reagents only			
Benzylpenicilloate or benzylpenilloate only	12 (20.0%)	39 (16.0%)	28 (26.2%)
PPL or benzylpenicillin only	32 (53.3%)	Not reported	Not reported
Benzylpenicilloate, benzylpenilloate, or amoxicillin only	16 (26.7%)	Not reported	Not reported
Benzylpenicillin, benzylpenicilloate, or benzylpenilloate only	15 (25.0%)	55 (22.6%)	30 (28.0%)

^aOutpatients.

^bInpatients.

^cMacy et al used commercially available PPL, whereas, because PRE-PEN was not commercially available in 2004, Lin et al synthesized the PPL for their trial. The site whose retrospective data Geng et al reported used PRE-PEN or PPL synthesized by the site according to published methods.

Beta-lactam Cross-reactivity

																					-								
	Cefazolin (1 st)	Cefaclor (2 nd)	Cefadroxil (1st)	Cefamandole(2 nd)	Cefdinir (3 rd)	Cefepime (4 th)	Cefixime (3 rd)	Cefoperazone (3rd)	Cefotaxime (3 rd)	Cefotetan (2 nd)	Cefoxitin(2 nd)	Cefpirome(4 th)	Cefpodoxime (3 rd)	Cefprozil (2 nd)	Ceftazidime (3 rd)	Ceftolozane (2nd)	Ceftibuten (3 rd)	Ceftizoxime (3rd)	Ceftriaxone (3 rd)	Cefuroxime (2 nd)	Cephalexin (1 st)	Cephaloridine (1st)	Cephradine (1st)	Cefditoren (3 rd)	Ceftaroline (5 th)	Amoxicillin	Ampicillin	Penicillin G	Aztreonam
Cefazolin (1 st)	-																												
Cefaclor (2 nd)		-	Ľ	X										Ħ							r		Ħ			Ħ	Ħ		
Cefadroxil (1st)		Ħ	-	L										R							Ħ		R			Ħ	Ħ		
Cefamandole (2 nd)		M	Ľ	•				H		Z				Ħ							Ħ		Ħ			Ħ	Ħ		
Cefdinir (3 rd)					-		J.																						
Cefepime (4 th)						-	Ľ		Ħ			Ľ	H		H	Ħ		z	Ħ	Ľ				Ħ					H
Cefixime (3 rd)					Ľ	Ħ	•		Ħ			Ħ	Ħ		Ħ	Ħ		Ħ	Ľ	Ľ				Ħ					Ħ
Cefoperazone (3rd)				Ħ				-		Ħ																			
Cefotaxime (3 rd)						Ħ	3C		-			Ħ	Ħ		Ħ	a		2ª	Ħ	H				Ħ					L
Cefotetan(2 nd)				Ħ				J.		-																			
Cefoxitin(2 nd)											-									z		Ħ						Ľ	
Cefpirome(4th)						Ľ	Ľ		Ľ			-	Ħ		Ľ	J.		Ħ	Ľ	Ħ				Ľ					Ħ
Cefpodoxime (3 ^d)						Ħ	H		Ħ			Ħ	-		Ħ	Ħ		Ħ	Ħ	Ħ				t					Ħ
Cefprozil(2 nd)		22	22	Ħ										-							11		H			Ħ	Ħ		
Ceftazidime (3 rd)						A	22		Ħ			H	X		-	R		X	22	H				X					Ħ
Ceftolozane (2nd)						Ħ	Ħ		Ħ			Ħ	Ħ		Ħ	•		Ħ	Ħ	Ħ				Ħ					Ħ
Ceftibuten (3rd)																	-	Ħ											
Ceftizoxime (3rd)						Ħ	J.		Ħ			Ħ	Ħ		H	Ħ	Ħ	-	Ħ	Ħ				Ħ					H
Ceftriaxone (3 rd)						X.	Ħ		Ħ			Ħ	Ħ		Ħ	Ħ		Ħ	-	H				z					Ľ
Cefuroxime(2 nd)						Ħ	Ľ		Ħ		Ħ	Ħ	Ħ		Ħ	Ħ		Ħ	Ľ	-				Ľ					Ħ
Cephalexin (1 st)		H	Ħ	Ħ										Ħ							-		Ľ			Ħ	H		
Cephaloridine (1st)											Ħ											-						Ħ	
Cephradine (1 st)		Ħ	22	Ħ										H							r		-			Ħ	Ħ		
Cefditoren (3rd)						t	L		Ħ			Ħ	L		Ħ	Ħ		22	H	Ħ				-					H
Ceftaroline (5th)																									-				
Amoxicillin		Ħ	L	Ľ										Ľ							Ħ		Ľ			-	Ħ		
Ampicillin		X	Ħ	Ħ										Ħ							Ħ		Ħ			Ħ	-		
Penicillin G											H											Ħ						-	
Aztreonam						Ħ	22		Ħ			Ħ	a		H	D		X	22	n				11					-

Current Penicillin hypersensitivity testing recommendations

Direct oral amoxicillin challenge can be performed in any patients with a history of the following symptoms associated with penicillin occurring more than 12 months ago:

- Any benign rash
- GI symptoms
- Headaches
- Other benign somatic symptoms
- Unknown history

Request allergy to penicillin skin test first if

- The reaction to penicillin has occurred within the past 12 months
- The patient has any history of shortness of breath or anaphylaxis associated with penicillin

and proceed to amoxicillin challenge only if skin test negative

Do not perform any penicillin allergy testing if there is a history of penicillin-associated

- Blistering rash involving $\geq 10\%$ of body surface area with skin loss
- Hemolytic anemia
- Nephritis
- Hepatitis